Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment
- Conditions
- Retinal Detachment
- Interventions
- Procedure: suprachoroidal buckling
- Registration Number
- NCT04518696
- Lead Sponsor
- Fang Wang
- Brief Summary
Study of novel surgical technic-suprachoroidal buckling for therapy of rhegmatogenous retinal detachment.It was excpted to reattached the retina and improve visual function of rhegmatogenous retinal detachment patients.
- Detailed Description
The operation was performed under a surgical microscope with a 25G Chandelier light source and a wide-field observation system to observe the fundus.Location, marking and freezing of the retinal tear on the scleral side .
Subretinal fluid is released from the outside of the sclera as needed. The spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. A "pocket" is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube (a 23 caliber curved tube with olive tip). The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Monitor the location of retinal tear during intubation in real time, and adjust the position of the needle: posterior margin of the tear. Once confirmed in accord with the needle position, sodium hyaluronate injection, injection needles to in front of shift to injection, until the tear was completely surrounded in viscoelastic agent to create the choroid crest, usually need 0.2 mL to 0.5 mL. Exit the duct and close the incision with scleral presutures.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
- (1) Clinical diagnosis of rhegmatogenous retinal detachment; (2)myopia < 600 degrees; (3) retinal tear were peripheral part, non-proliferative round hole or horseshoe tear, single or multiple tears within one oclock area; (4) PVR grading: Grade A, B, C1, C2; (5) Subretinal fluid was confined around the tear. (6)phakic.
- (1)Cataract, corneal degeneration, genetic diseases; (2)History of internal eye surgery; (3)The other eye was blind; (4)Postoperative follow-up could not be scheduled; (5)Systemic diseases (asthma, heart failure, myocardial infarction, liver failure, kidney failure and other serious diseases); (6)History of aspirin and other anticoagulant drugs; (7)Severe adverse reactions and systemic diseases occurred during follow-up.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description suprachoroidal buckling treatment group suprachoroidal buckling suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
- Primary Outcome Measures
Name Time Method Treatment-related adverse event 3 months post operation Number of participants with treatment-related adverse events(including suprachoroidal hemorrhage, subretinal hemorrhage, vitreous hemorrhage)
Retina reattachment 3 months post operation Number of participants who achieved retina reattachment assessed by fundus photography,b-scan ultrasonography and optical coherence tomography.
Best Corrected visual Acuity (BCVA) 3 months post operation Patients' best corrected visual acuity assessed by logarithmic visual acuity charts.
Intraocular pressure (IOP) 3 months post operation Patients' IOP assessed by noncontact tonometer
- Secondary Outcome Measures
Name Time Method Best Corrected visual Acuity (BCVA) 12 months post operation Patients' best corrected visual acuity assessed by logarithmic visual acuity charts.
Intraocular pressure (IOP) 12 months post operation Patients' IOP assessed by noncontact tonometer
Retina reattachment 12 months post operation Number of participants who achieved retina reattachment assessed by fundus photography,b-scan ultrasonography and optical coherence tomography.
Treatment-related adverse event 12 months post operation Number of participants with treatment-related adverse events(including suprachoroidal hemorrhage, subretinal hemorrhage, vitreous hemorrhage)